Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.

Biotechnology

Manufacturing

Oxford Biomedica Solutions

Tim Kelly

Ryan Dickerson

Melissa P.

Kelly Quesada

Volker Glidden

Stephen Boyd

Marissa Stanvick

Diane Golebiowski

David Hamilton

Lori Karpes

Amy P.

Patricia Daggett

The Quality Control and Assurance Team at Oxford Biomedica Solutions ensures the integrity and compliance of AAV and lentiviral-based cell and gene therapies manufacturing processes. This team, comprising specialists in QC analysis, regulatory and product quality, quality systems, and compliance, rigorously tests and monitors products to meet stringent industry standards and regulatory requirements. They implement and manage quality systems, perform molecular biology and chemistry analyses, and ensure that each product meets the highest quality criteria before reaching patients.

Quality Control and Assurance Team

Research and Development

Director Team

Quality Control and Assurance Team

About

Team members

Other teams at Oxford Biomedica Solutions

Research and Development

Director Team